Eloxx Pharmaceuticals (ELOX) and Its Rivals Critical Comparison

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its risk, valuation, dividends, earnings, profitability, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Eloxx Pharmaceuticals and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7643	13710	25539	1011	2.42

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, indicating a potential upside of 150.38%. As a group, “Pharmaceuticals” companies have a potential upside of 37.70%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Valuation and Earnings

This table compares Eloxx Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-9.94
Eloxx Pharmaceuticals Competitors	$3.56 billion	$3.15 billion	544.86

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.24%	-223.52%	-17.00%

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.17, meaning that their average stock price is 417% less volatile than the S&P 500.

Summary

Eloxx Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.